Articles
7,623 Articles
Psychedelics Today
/
Nov 22, 2024
Sex and Psychedelics: Healing Through Altered States
Can erotic energy be as transformative as a psychedelic experience? In this episode, Joe interviews Bria Tavakoli, LPCC, MA, MS: a therapist specializing in relational and sex therapy, with a focus on helping clients integrate psychedelic experiences. She shares her personal journey with...
Psilocybin Alpha
/
Nov 22, 2024
Pα+ Psychedelic Bulletin #181: Last-Minute Changes to Colorado’s Psychedelics Rules; Cybin’s Impressive 12-Month Data Overshadowed by Small N and Controversial Marketing Move
As Colorado’s state-regulated psychedelics system comes ever closer to its launch next year, last-minute changes to its rules are causing commotion. With fewer than forty days to go until the state begins accepting license applications, and two years after voters endorsed Prop. 122 in the November...
Psychedelics
Zen Habits
/
Nov 22, 2024
The Joy of Taking Care of My Life
By Leo Babauta When I was younger, I had a hard time doing some basic things like: Paying billsKeeping the house cleanRunning errandsDoing yard workDoing car and house maintenanceTaking care of my healthStay on top of work tasksI always knew that I “should” do these things, but they felt like...
Psychedelic Invest
/
Nov 21, 2024
Cannabis for PTSD: MAPS’ MJP2 Trial Approved
In a pivotal achievement for mental health and cannabis research, the Multidisciplinary Association for Psychedelic Studies (MAPS) has overcome substantial regulatory barriers to advance its Phase 2 clinical trial, known as MJP2. This groundbreaking study examines the effects of smoked and vaporized...
Cannabis
Microdose
/
Nov 21, 2024
MAPS Successfully Clears Path for Cannabis Research through FDA Formal Dispute
In a historic win for mental health and cannabis research, the Multidisciplinary Association for Psychedelic Studies (MAPS) has cleared significant regulatory hurdles to move forward with its Phase 2 clinical trial, MJP2, which investigates the effects of smoked and vaporized cannabis on...
Cannabis
DoubleBlind Mag
/
Nov 21, 2024
How Queer Nightlife Is a Portal to Ritual, Healing, and Belonging
Cedric Antonio is the only person who has ever denied me entry to a party. This almost-perfect track record isn’t because of status or looks or money, or anything like that; it’s because I just love door people! We always hit it off. Along with strippers and phlebotomists, they are among my...
DoubleBlind Mag
/
Nov 21, 2024
Quotes That Put the “Magic” in Mushrooms
Mushrooms have a mind of their own. Their ability to quite literally infiltrate brains has spawned many a sci-fi plot, and some even hold shrooms responsible for the evolution of humankind. They span a wide variety, from classic psychedelic mushrooms like Psilocybe cubensis to medicinal mushrooms...
DoubleBlind Mag
/
Nov 21, 2024
Scientists Think DMT Is Responsible for Life’s Most Mysterious Experiences
DMT, the fast-acting psychedelic that transports its users to otherworldly plains populated by machine elves and Incan priestesses, can be found “almost everywhere you choose to look,” wrote psychedelic chemist Alexander Shulgin. “DMT is … in this flower here, in that tree over there, and in...
DMT
Ketamine
Psychedelics
DoubleBlind Mag
/
Nov 21, 2024
New Michigan Bill Will Legalize Psilocybin Mushrooms for PTSD Patients If Passed
Newly introduced legislation in Michigan would clear the way for people with post-traumatic stress disorder (PTSD) to legally possess and use psychedelic mushrooms. Sponsored by Rep. Mike McFall (D), HB 5980 would legalize possession of up to two ounces of “a substance that contains psilocybin”...
Psilocybin
Psychedelic Invest
/
Nov 20, 2024
Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing
NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the favorable outcome of the Nasdaq Listing Qualifications Hearing that was held on October 31st, 2024. The Nasdaq Hearings Panel has granted Psyence...
DoubleBlind Mag
/
Nov 20, 2024
Turn On, Tune In, and Get a Degree in Psychedelics
In the ‘60s, Timothy Leary’s mantra — “turn on, tune in, and drop out” — became a rallying cry for students. It stood as an invitation to reject convention and embrace a different kind of enlightenment. But now, thanks to the mainstreaming of psychedelics, they can turn on, tune in, and...
MDMA
Psychedelics
Psychedelics - Green Market Report
/
Nov 20, 2024
Psyence Biomedical to consolidate shares in bid to keep Nasdaq listing
Psyence Biomedical Ltd. (Nasdaq: PBM) will implement a 1-for-75 share consolidation next week as the psychedelics company works to maintain its Nasdaq listing, the company said Tuesday. The consolidation will take effect at market open on Nov. 26, with shares continuing to trade under the ticker...
Psychedelic Invest
/
Nov 20, 2024
Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation
NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced an effective date for its previously-announced share consolidation. At its Annual General and Special Meeting of Shareholders, which was held...
DoubleBlind Mag
/
Nov 19, 2024
Down the Rabbit Hole with “White Rabbit” Mushrooms
When we think of “White Rabbit,” many of us are likely to think of Alice In Wonderland and the white rabbit who rushes in from offscreen, “I’m late! I’m late! For a very important date! No time to say hello, goodbye!” then disappears down a rabbit hole. Led by Alice, who out of curiosity...
Psilocybin
Psychedelic Invest
/
Nov 19, 2024
Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™
Lobe Sciences, Ltd. (“Lobe Sciences” or the “Company”) (CSE: LOBE), (OTCQB: LOBEF) and Alera Pharma, Inc. (“Alera” or “Alera Pharma”), biopharmaceutical companies focused on developing products to treat diseases with significant unmet medical needs, today announce that a second...
Psilocybin
Psilocybin Alpha
/
Nov 19, 2024
Psychedelic Investor Survey Q3 2024
Topline results from the latest in our series of psychedelics investor surveys. ∎ In late Q3’24, we distributed our Psychedelics Investor Survey. Prior to that, our last survey was back in Q4 2022, making this latest instalment long overdue.Indeed, lots has changed in that nearly two-year...
Psychedelics
Psychedelics Today
/
Nov 19, 2024
Standards, Ethics, and Integration: Rebuilding Trust in the Ketamine Industry
While the psychedelic industry is facing intense growing pains, the ketamine industry has been allowed to grow, largely unchecked. How did we get here, and how does the ketamine space rebuild trust? In this episode, Kyle interviews Juan Pablo Cappello: co-founder and former CEO of Nue Life Health,...
Ketamine
Psychedelic Invest
/
Nov 19, 2024
Braxia Scientific Announces Change in Directors and CEO
Toronto, Ontario–(Newsfile Corp. – November 18, 2024) – Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) (“Braxia”, or the “Company”) announced that Jerry Habuda has resigned as a director effective November 12, 2024. Peter Rizakos was appointed on the same date by the...
Psychedelic Invest
/
Nov 18, 2024
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
TORONTO, November 18, 2024–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company“), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options,...
Psychedelic Invest
/
Nov 18, 2024
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
NEW YORK–(BUSINESS WIRE)–Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief...
Microdose
/
Nov 18, 2024
Introduction to Jill Sitnick: A Courageous Journey from Healing to Advocacy
When I first spoke with Jill Sitnick, founder of Journey Sage LLC, I was struck by her candidness and determination to share a story that is both deeply personal and profoundly important. Jill’s journey from grappling with debilitating PTSD to becoming a passionate advocate for MDMA-assisted...
Psilocybin
MDMA
Psychedelic Invest
/
Nov 18, 2024
PharmaDrug Announces Issuance of Debenture Units
Toronto, Ontario–(Newsfile Corp. – November 15, 2024) – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines and...
Psychedelic Invest
/
Nov 18, 2024
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
SARASOTA, FL, Nov. 18, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today...
DoubleBlind Mag
/
Nov 18, 2024
The Psilocybin Mushroom Market Is Expected To Reach $3.3 Billion by 2031
The psychedelic mushrooms market is headed for a billion-dollar payday, according to a new market forecast report. The Persistence Market Research report projects the global psychedelic mushrooms market will reach $3.3 billion by 2031. For comparison, the all-terrain vehicle or ATV market is...
Psilocybin
MDMA
Psychedelic Invest
/
Nov 18, 2024
Numinus Applies for Management Cease Trade Order
VANCOUVER, BC, Nov. 15, 2024 /PRNewswire/ – Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) (“Numinus” or the “Company“), a leader in mental health care specializing in innovative and evidence-based treatments, announces that it has requested a temporary Management Cease Trade Order...
DoubleBlind Mag
/
Nov 18, 2024
Mushroom Gummies 101: Here’s Everything You Need to Know
So you want to buy mushroom gummies but don’t know where to start? You’re in luck! We wrote this to help guide you from the mystical to the practical, offering insight for the most informed choice — plus, we include a recipe to boot. What Are Mushroom Gummies? Mushroom gummies are the chewy...
Psilocybin
Ayahuasca
Psychedelic Invest
/
Nov 15, 2024
Filament Health Announces Third Quarter 2024 Financial Results and Operational Highlights
VANCOUVER, BC, Nov. 14, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, released its third quarter financial results and operational highlights for the period...
Psilocybin Alpha
/
Nov 15, 2024
Pα+ Psychedelic Bulletin #180: Mass. Psychedelics Ballot Post-Mortem Begins; Cybin Commences Phase 3; CaaMTech Claims It’s Solved Functional Unblinding
Last-minute donations from Dr. Bronner’s ($100k), Elliot Cohen ($100k), Eliza Dushku ($100k), MAPS ($50k), and others could not push Question 4 over the line, with the Massachusetts ballot initiative suffering defeat by a convincing margin. (See Question 4 Fails: Massachusetts Says No to...
Psychedelics
Psychedelics - Green Market Report
/
Nov 15, 2024
Enveric Biosciences narrows net loss, advances lead drug candidate
Enveric Biosciences Inc. (NASDAQ: ENVB) reported its financial results for the third quarter of 2024 and provided a corporate update yesterday. Enveric said it made “important progress” in the development of EB-003, its lead neuroplastogenic molecule designed to treat depression, anxiety and...
DMT
Zen Habits
/
Nov 15, 2024
Thoughts on Healthy Eating
By Leo Babauta Eating healthy is something I’ve been a bit obsessed with for the last couple of decades, and I’ve transformed my eating in some really fundamental ways: I eat way less junk food than beforeI have developed a real love for whole, nutritious foodsI’m vegan (for ethical reasons)I...
Psychedelics - Green Market Report
/
Nov 15, 2024
Numinus to sell five Utah ketamine clinics to Stella for $3.5M in tech pivot
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) agreed to sell its five Utah clinics to psychiatric care provider Stella. The deal will also create a data-sharing partnership to develop clinic management software, as the struggling psychedelics company moves away from direct patient care. The...
LSD
MDMA
Psychedelic Invest
/
Nov 15, 2024
Numinus Wellness Announces Sale of Clinics and Unique Data Partnership to Increase Access to Mental Health Care
VANCOUVER, BC, Nov. 15, 2024 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company“) (TSX: NUMI) (OTCQX: NUMIF) (FSE: LR23), a mental healthcare company advancing traditional and innovative behavioral health treatments including safe, evidence-based psychedelic-assisted...
Psychedelics - Green Market Report
/
Nov 15, 2024
Filament Health revenue slides 94% as cash reserves dwindle
Vancouver-based Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) saw its cash reserves continue to decline as third-quarter revenue plummeted to $19,021, from $337,470 in the same period last year, according to financial results Thursday. The clinical-stage psychedelic drug development firm ended...
Psychedelics Today
/
Nov 15, 2024
From Individualism to Connection: How Psychedelics and Group Therapy Can Heal Our Collective Crisis
It becomes more apparent every day how much isolation and focusing so much on the individual is hurting us. Can psychedelics – and specifically, group therapy – be the answer to our crisis of individualism? In this episode, Kyle interviews Geoff Bathje, Ph.D.: licensed psychologist, researcher,...
Psychedelics
Psychedelic Invest
/
Nov 14, 2024
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it will host a...
Psychedelic Invest
/
Nov 14, 2024
PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License
TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), has...
MDMA